Trial Profile
A Randomized, Positive Parallel Controlled, Multicenter Phase III Study of TQB2450 Injection Combined With Anlotinib Hydrochloride Capsule Versus Paclitaxel for Injection (Albumin Bound) in Subjects With Triple Negative Breast Cancer (TNBC)
Status:
Not yet recruiting
Phase of Trial:
Phase III
Latest Information Update: 07 Jul 2022
Price :
$35
*
At a glance
- Drugs Benmelstobart (Primary) ; Catequentinib (Primary) ; Paclitaxel
- Indications Advanced breast cancer; Male breast cancer; Triple negative breast cancer
- Focus Registrational; Therapeutic Use
- Sponsors Chia Tai Tianqing Pharmaceutical Group
- 29 May 2020 New trial record